logo_tumThe Leiden University Medical Center or LUMC, is the university hospital affiliated with Leiden University, located in Leiden, Netherlands, of which it forms the medical faculty. It resulted from the merger of the Academisch Ziekenhuis Leiden (Leiden Academic Hospital) and the medical faculty of Leiden University in the late 1990s, forming an academic health science centre. Similar arrangements exist for most university hospitals in the Netherlands. The hospital has clinical departments of all medical specialties, and acts as a tertiary referral centre for the northern part of the province of South Holland. In addition, it has a wide range of research programmes in both clinical and basic medical research, leading to a large output of scientific publications.


Lead Scientist: Prof. Martin Hildebrandt, MD

Institution: TUM Cells TU München
Position: Executive Director

Contact Information

email: martin.hildebrandt[at]lrz.tum.de
Telephone: (+) 49 89 41407810
Address: Ismaninger Strasse 22, 81675 München, Germany

Professor Martin Hildebrandt is in charge of this GMP facility. The major area of research of Martin Hildebrandt is T-cell mediated immunomodulation and Transplant optimisation.

Prof. Hildebrandt is a member of the working group on blood-associated infectious risks at the Federal Ministry of Health, head of a sub-committee at the City of Berlin’s ethics committee, member of the committee on laboratory practices within the International society for Cellular Therapy (ISCT) and member of several national and international professional societies.

As a GMP expert, he is involved as a partner in the FP7 project BIOHYBRID, and has coordinated “Academic GMP”, an FP7- funded research project that, in many aspects, has laid a basis for the AGORA proposal presented here.
Tasks: Professor Hildebrandt leads WP3 and participates in WP2 as the director of the training programme at to be created at TUM-Med. He also participates in WP4 and have a substantial role in WP5.

Selected publications:

1. M Hildebrandt, C Bollard, K Peggs, L Uharek, HE Heslop. Immunotherapy: Opportunities, Risks, and future Perspectives. Cytotherapy, in press.

2. G Pauli, U Bauerfeind, J Blümel, R Burger, C Drosten, A Gröner, L Gürtler, M Heiden, M Hildebrandt, B Jansen, T Montag-Lessing, R Offergeld, R Seitz, U Schlenkrich, V Schottstedt, J Strobel, H Willkommen. West Nile Virus. Transfus Med Hemother. 2013 Aug;40(4):265-84. doi: 10.1159/000353698. Epub 2013 Jul 4.

3. M Hildebrandt, N Forgó. Short Report: Joint Conference on The Impact of EU Legislation on Therapeutic Advance. Cytotherapy. 2013 Dec;15(12):1444-8. doi: 10.1016/j.jcyt.2013.06.011. Epub 2013 Aug 28.

4. M Hildebrandt, D Dijkstra, H Gollasch, K Daemen, M Stevanovic-Meyer, WD Ludwig. Apheresis-related enrichment of CD26++ T lymphocytes: phenotypic characterization and correlation with unfavorable outcome in autologous hematopoietic progenitor cell transplantation. Transfusion. 2011; 52(4):765-76.

5. O Cohen-Haguenauer, N Creff, P Cruz, C Tunc, A Aïuti, C Baum, F Bosch, P Blomberg, K Cichutek, M Collins, D Danos, F Dehaut , M Federspiel , E Galun, H Garritsen, H Hauser, M Hildebrandt, D Klatzmann , OW Merten , E Montini , T O’Brien , A Panet , L Rasooly , D Scherman, M Schmidt, M Schweitzer, P Tiberghien, T Vandendriessche, H Ziehr, S Ylä-Herttuala, C von Kalle, G Gahrton, M Carrondo. Relevance of an academic GMP Pan-European vector infra-structure (PEVI). Curr Gene Ther. 2010; 10(6):414-22.